Tanja is the CEO of Debiopharm Innovation Fund, the investment arm of Debiopharm based in Lausanne, Switzerland. With 150M under management, the fund invests in digital health and therapeutic platform start-ups that radically improve patient journeys and pharmaceutical R&D. Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder/CEO at BioSolutions INT. During her years in consulting and investment, Tanja has worked with more than 80 medical & healthcare companies globally, giving her a broad view into innovative product development, commercial strategies, and building winning teams. Tanja is an experienced board member and chairwoman with a track record of successful M&A exits. She holds an MSc in Applied Microbiology and Biochemistry from Helsinki University of Technology.
From utilizing patient portals and other electronically accessible data to using wearable tech for monitoring blood pressure, cholesterol levels, and other measurables, patients today have a wide range of available options to ensure they are taking an active role in their own healthcare journey.
AI’s ability to quickly scan and synthesize huge volumes of information is being adopted for numerous healthcare initiatives, including use in pharmaceutical drug discovery and development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.